MKI67 and neuroendocrine carcinoma: There was a significant difference (p < 0.001) in OS between NEC (median of 13.4 months, 95% CI 10.8–19.4 months) and NET G3 (median of 44.7 months, 95% CI 39.2–NA months) as well as between high Ki-67 index (> 55%) with a median of 13.7 (95% CI 10.8–21.2 months) and patients with a Ki-67 proliferation index below that cut-off (median of 39.7 months, 95% CI 21.7–97.2 months).